Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Quinoxaline, 2-methyl-7-nitro- (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

120885-31-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 120885-31-6 Structure
  • Basic information

    1. Product Name: Quinoxaline, 2-methyl-7-nitro- (9CI)
    2. Synonyms: Quinoxaline, 2-methyl-7-nitro- (9CI)
    3. CAS NO:120885-31-6
    4. Molecular Formula: C9H7N3O2
    5. Molecular Weight: 189.17078
    6. EINECS: N/A
    7. Product Categories: VARIOUSAMINE
    8. Mol File: 120885-31-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Quinoxaline, 2-methyl-7-nitro- (9CI)(CAS DataBase Reference)
    10. NIST Chemistry Reference: Quinoxaline, 2-methyl-7-nitro- (9CI)(120885-31-6)
    11. EPA Substance Registry System: Quinoxaline, 2-methyl-7-nitro- (9CI)(120885-31-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 120885-31-6(Hazardous Substances Data)

120885-31-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 120885-31-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,8,8 and 5 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 120885-31:
(8*1)+(7*2)+(6*0)+(5*8)+(4*8)+(3*5)+(2*3)+(1*1)=116
116 % 10 = 6
So 120885-31-6 is a valid CAS Registry Number.

120885-31-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-methyl-7-nitroquinoxaline

1.2 Other means of identification

Product number -
Other names 3-methyl-6-nitroquinoxaline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:120885-31-6 SDS

120885-31-6Relevant articles and documents

Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition

-

Paragraph 0247-0251, (2021/07/10)

The invention belongs to the technical field of compound synthesis, and particularly relates to a method for synthesizing quinoxaline compounds under visible light induced iron catalysis conditions. The method comprises the following steps: by taking non-activated aliphatic amine and o-phenylenediamine as raw materials, under the action of a photosensitizer, under the illumination of visible light, reacting in a solvent at room temperature and under oxygen conditions to generate the quinoxaline compound. The method has better substrate universality and relatively mild reaction conditions, not only realizes synthesis of the quinoxaline compound for the first time, but also widens the field of organic synthesis.

New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models

Le Douaron, Gael,Ferrié, Laurent,Sepulveda-Diaz, Julia E.,Amar, Majid,Harfouche, Abha,Séon-Méniel, Blandine,Raisman-Vozari, Rita,Michel, Patrick P.,Figadère, Bruno

, p. 6169 - 6186 (2016/07/26)

Parkinson's disease (PD) is a neurodegenerative disorder of aging characterized by motor symptoms that result from the loss of midbrain dopamine neurons and the disruption of dopamine-mediated neurotransmission. There is currently no curative treatment for this disorder. To discover druggable neuroprotective compounds for dopamine neurons, we have designed and synthesized a second-generation of quinoxaline-derived molecules based on structure-activity relationship studies, which led previously to the discovery of our first neuroprotective brain penetrant hit compound MPAQ (5c). Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder.

Novel highly regioselective syntheses of unsymmetrical 2,3-disubstituted quinoxalines

Hui, Xu,Schmidt, Fanny,Fakhfakh, Mohammed Akram,Franck, Xavier,Figadère, Bruno

, p. 353 - 361 (2008/03/12)

Non-symmetrical 2,3-disubstituted quinoxalines are not easily obtained in good yields because of the lack of regioselectivity of the Hinsberg condensation, or the large number of steps required for achieving their preparation. Two efficient methods leadin

Synthesis of the Food Mutagens MeIQx and 4,8-DiMeIQx by Copper(I) Promoted Quinoxaline Formation

Knapp, Spencer,Ziv, Joseph,Rosen, Joseph D.

, p. 1293 - 1298 (2007/10/02)

The regiocontrolled syntheses of the title compounds (1 and 2) is described.The key step is a new intramolecular alkyne amination and aromatization process (5 6; 8 9) effected by tetrakis(acetonitrile)copper(I) tetrafluoroborate.

1,4,5,8-TETRA-AZAPHENANTHRENE COMPLEXES OF COPPER(I) AND SILVER(I)

Nasielski, J.,Nasielski-Hinkens, R.,Heilporn, S.,Rypens, C.,Declercq, J. P.

, p. 983 - 992 (2007/10/02)

Cu(I) and Ag(I) complexes of 1,4,5,8-tetra-azaphenanthrene (TAP) and of two its methylated derivatives (3,6-dimethyl- and 2,3,6,7-tetramethyl-) have been made and characterized.Their 1HNMR spectra are discussed.The structure of the complex Ag(TAP)2(NO3), as determined by X-Ray crystallography, is that of strongly folded and twisted square planar arrangement of the chelating ligands around the silver atom; the four Ag-N bonds are not equal: they are shorter (2.36 Angstroem) in one pair of trans bonds than in the other (2.56 Angstroem). 3,6-Dimethyl-1,4,5,8-tetra-azaphenanthrene (3,6dmTAP), a new TAP derivative, has been synthesized starting from 2-hydroxy-3-methylquinoxaline which was nitrated, then treated with POCl3, the resulting 2-chloro-3-methyl-6-nitroquinoxaline reacted with hydrazine and the hydrazino group oxidized to give 3-methyl-6-nitroquinoxaline.This was aminated with hydroxylamine, reduced to the diamine and finally condensed with glyoxal to give 2,6-dimethyl- and 3,6-dimethyl-1,4,5,8-tetra-azaphenanthrene.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 120885-31-6